• Etie Moghissi and Allen B King.
• Department of Medicine, University of California Los Angeles, Los Angeles, Calif. Electronic address: emoghissi@gmail.com.
• Am. J. Med. 2014 Oct 1; 127 (10 Suppl): S3S10S3-10.

AbstractIt is recognized that reducing hyperglycemia early on in disease progression has long-term benefits for patients with diabetes. Insulin therapy has greater potential to reduce hyperglycemia than other therapies; however, there is often a significant delay in insulin initiation and intensification. Insulin replacement therapy in type 2 diabetes should no longer be viewed as the treatment of last resort. With the development of modern insulin analogs, the field has evolved. Large clinical trials have improved our understanding of the potential benefits and risks associated with intensive glycemic control in different patient populations and highlighted the need for individualization of glycemic targets and treatment strategies. Current treatment guidelines recognize the important role of insulin therapy both early on and throughout the progression of type 2 diabetes.Copyright © 2014 The Authors. Published by Elsevier Inc. All rights reserved.

32 keywords...

hide…